Search Results - "Dalban, C."

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF by Chauffert, B., Feuvret, L., Bonnetain, F., Taillandier, L., Frappaz, D., Taillia, H., Schott, R., Honnorat, J., Fabbro, M., Tennevet, I., Ghiringhelli, F., Guillamo, J.S., Durando, X., Castera, D., Frenay, M., Campello, C., Dalban, C., Skrzypski, J., Chinot, O.

“…Prognosis of unresectable glioblastoma (GB) remains poor, despite temozolomide (TMZ)-based chemoradiation. Activity of bevacizumab (BEV) and irinotecan (IRI)…”
Get full text

Brain metastases response to nivolumab in patients with renal cell carcinoma (RCC): Prospective analysis from the GETUG-AFU 26 (NIVOREN) trial by Flippot, R., Dalban, C., Laguerre, B., Borchiellini, D., Gravis, G., Negrier, S., Chevreau, C.M., Joly, F., Geoffrois, L., Ladoire, S., Mahammedi, H., Tantot, F., Escudier, B., Albiges, L.

Get full text

Alienor/ENGOT-ov7 randomized trial exploring weekly paclitaxel (wP) + bevacizumab (bev) vs wP alone for patients with ovarian sex cord tumors (SCT) in relapse by Ray-Coquard, I.L., Harter, P., Lorusso, D., Dalban, C., Vergote, I.B., Fujiwara, K., Gladieff, L., Lueck, H.-J., Floquet, A., Lesoin, A.F., Schnelzer, A., Pignata, S., Selle, F., Sehouli, J., Brocard, F., Mangili, G., Pautier, P., De Giorgi, U., Provansal, M., Heudel, P.-E.

Get full text

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial by Ladoire, S., Mignot, G., Dalban, C., Chevriaux, A., Arnould, L., Rébé, C., Apetoh, L., Boidot, R., Penault-Llorca, F., Fumoleau, P., Roché, H., Spielmann, M., Levy, C., Lortholary, A., Eichler, F., Mesleard, C., Bonnetain, F., Ghiringhelli, F.

“…Predictive markers of response to chemotherapy are lacking in breast cancer patients. Forkhead Box Protein 3 (FOXP3) is an anti-oncogene whose absence in…”
Get full text

2069 Elective nodal irradiation during exclusive chemoradiation for locally-advanced esophageal cancer: IMRT better spares critical organs at risk by Jean-Mary, E, Dalban, C, Serre, A.A, Maingon, P, Petitfils, A, Mirjolet, C, Vulquin, N, Wiazzane, N, Crehange, G

Get full text

The Relationship Between the Occurrence of Bone Metastases and Dose/Volume of Prior Prostate Radiation Therapy in Patients With Localized Prostate Cancer by Crehange, G, Laporte, G, Dalban, C, Martin, E, Cochet, A, Cormier, L, Mirjolet, C, Desmoulins, I, Ladoire, S, Maingon, P

Get full text

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial by Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., Taieb, J., Brucker, P., Landi, B., Flesch, M., Carola, E., Martin, P., Vaillant, E., de Gramont, A.

“…The sequential FOLFOX7–FOLFIRI combination is not superior to FOLFOX4 in colorectal cancer patients with resectable metastases. Patients with synchronous…”
Get full text

2009 Tumoral lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer as a prognostic factor for survival: The LYMPHOREC study by Mirjolet, C, Charon-barra, C, Arbez-gindre, F, Gauthier, M, Maingon, P, Barthod, Z, Leroux, A, Merlin, J.L, Peiffert, D, Dalban, C, Ladoire, S, Bosset, J.F, Crehange, G

Get full text

Correlation between radio-induced lymphocyte apoptosis measurements obtained from two French centres by Mirjolet, C., Merlin, J.L., Dalban, C., Maingon, P., Azria, D.

“…In the era of modern treatment delivery, increasing the dose delivered to the target to improve local control might be modulated by the patient's intrinsic…”
Get full text

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with perioperative or postoperative chemotherapy from an open-label, randomized phase III trial by Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., de Gramont, A.

Get full text

A phase I dose escalation study using simultaneous integrated-boost IMRT with temozolomide in patients with unifocal glioblastoma by Truc, G., Bernier, V., Mirjolet, C., Dalban, C., Mazoyer, F., Bonnetain, F., Blanchard, N., Lagneau, É., Maingon, P., Noël, G.

“…To evaluate the maximum tolerated dose of simultaneous integrated-boost intensity-modulated radiotherapy (SIB-IMRT) associated with temozolomide in patients…”
Get full text

Reirradiations of head and neck cancers: state of the concept and ways of development by Soltys, B, Wiazzane, N, Mirjolet, C, Dalban, C, Serre, A A, Zanetta, S, Thiebaut, S, Créhange, G, Maingon, P

“…The treatment of local recurrence or second primary developed in irradiated area in the field of head and neck carcinoma, should be planned and organized…”
Get full text

Tolerability of anti-tuberculosis treatment and HIV serostatus by Lanternier, F, Dalban, C, Perez, L, Bricaire, F, Costagliola, D, Caumes, E

“…SETTING: Tuberculosis (TB) is frequent in human immunodeficiency virus (HIV) infected patients, but its treatment is hampered by adverse events and paradoxical…”
Get full text

The long‐term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model‐based approach by Yazdanpanah, Y, Vray, M, Meynard, J, Losina, E, Weinstein, MC, Morand‐Joubert, L, Goldie, SJ, Hsu, HE, Walensky, RP, Dalban, C, Sax, PE, Girard, PM, Freedberg, KA

“…Objectives Resistance testing in HIV disease may provide long‐term benefits that are not evident from short‐term data. Our objectives were to estimate the…”
Get full text

Pulmonary manifestations of leptospirosis by Paganin, F, Bourdin, A, Borgherini, G, Dalban, C, Poubeau, P, Tixier, F, Gouix, A, Noel, J-B, Cotte, L, Arvin-Berod, C

“…Pulmonary manifestations in leptospirosis are considered a major complication, and are related to a poor prognosis. We present a large series of patients with…”
Get more information

Ré-irradiations des cancers de la tête et du cou : état du concept et voies de développement by Soltys, B., Wiazzane, N., Mirjolet, C., Dalban, C., Serre, A.A., Zanetta, S., Thiebaut, S., Créhange, G., Maingon, P.

“…La prise en charge des récidives ou deuxième cancer en zone irradiée des voies aérodigestives supérieures est dominée par la multidisciplinarité et bénéficie…”
Get full text

1909P Baseline cytokine levels according to the line of treatment in patients with metastatic clear cell renal cell carcinoma treated with nivolumab: NIVOREN GETUG-AFU 26 translational study by Rainho, L.T., Albiges, L., Flippot, R., Ajuria, L. Carril, Dalban, C., Escudier, B., Naigeon, M., Desnoyer, A., Teixeira, M., Chaput-Gras, N.

Get full text

O66 Prévalence élevée du diabète, proportion importante de diabétiques méconnus, altération de l’état de santé des diabétiques dépistés : des arguments en faveur d’une recherche-action sur le dépistage en population à la Réunion ? by Favier, F, Grimoire, R, Dalban, C, Naty, N, Porcherat, S, Picaud, J.B, Debussche, X, Le Moullec, N, Fagot-Campagna, A, Fianu, A

“…Introduction En 1999–2001 l’enquête Rédia chez 4610 personnes (18–69 ans), avait montré une prévalence de diabète de 14,8%. Sur un total de 682 diabétiques,…”
Get full text

EP-1641 Radiotherapy for prostate cancer patients over 80 years: 95 patients treated in a single institution by Méré, P., Dalban, C., Peynet, E., Guignot, A., Droz, J., Pommier, P.

Get full text

674P Initial curative management for localized/locally advanced head and neck squamous cell carcinomas (LAHNSCC): Exclusive (chemo)radiation (CRT) or S/IC (surgery or induction chemotherapy) – The EPOCKS study by Fayette, J., Dalban, C., Zrounba, P., Racadot, S., Girodet, D., Chabaud, S., Reyt, E., Poupart, M., Prades, J.M., Burgy, M., Cellier, D., Ceruse, P., Leval, J., Muller, P., Manipoud, P., Ray-Coquard, I.L., Thibault, G.

Get full text